Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» 177Lu-MSMA-617
177Lu-MSMA-617
Novartis' radioligand hits goal in phase 3 prostate cancer trial
Fierce Biotech
Tue, 03/23/21 - 10:29 am
Novartis
radioligand
177Lu-MSMA-617
prostate cancer
clinical trials